We are a biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat chronic energy balance disorders in metabolically challenged obese and/or elderly individuals. Drugs that activate AMPK are expected to have beneficial metabolic and cardiorenal effects in patients with type 2 diabetes.
Betagenon is financed by private Investors:
The foundation Stiftelsen J.C. Kempes Minne, www.kempe.com
Fort Knox AB, www.fort-knox.se